Artiva Biotherapeutics
is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). AlloNK is currently being evaluated in three ongoing clinical trials, including a company-sponsored basket trial across autoimmune diseases, which includes rheumatoid arthritis and Sjögren’s disease, and an investigator-initiated basket trial in B-cell driven autoimmune diseases.
Read More